Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities

Avirup Guha, Merna Armanious, Michael G. Fradley

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.
Original languageEnglish (US)
Pages (from-to)29-39
Number of pages11
JournalTrends in Cardiovascular Medicine
Issue number1
StatePublished - Jan 1 2019


  • Cardio-oncology
  • Cardiotoxicity
  • Proteasome inhibitors
  • Tyrosine kinase inhibitors


Dive into the research topics of 'Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities'. Together they form a unique fingerprint.

Cite this